Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.33 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383145 | 0.87 | L3MBTL1 (0.51) | L3MBTL3L3MBTL1MEN1KMT2ADRD2 | |
| SCHEMBL4381114 | 0.87 | L3MBTL1 (0.51) | L3MBTL3L3MBTL1MEN1KMT2ADRD2 | |
| SCHEMBL4383372 | 0.84 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1TP53BP1DRD2 | |
| SCHEMBL4388125 | 0.82 | GAA (0.45) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL4386340 | 0.81 | HRH3 (0.39) | L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL4388918 | 0.81 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1DRD2DRD3 | |
| SCHEMBL4384528 | 0.81 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1MEN1KMT2A | |
| SCHEMBL4383440 | 0.80 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL4384521 | 0.79 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1DRD2DRD3 | |
| SCHEMBL4382122 | 0.79 | CYP1A2 (0.43) | L3MBTL3L3MBTL1MEN1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | L3MBTL3 1965/4885L3MBTL1 2665/4885MBTD1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.